The design and analysis of vaccine trials for COVID-19 for the purpose of estimating efficacy

Stephen Senn

doi:10.1002/pst.2226

The design and analysis of vaccine trials for COVID-19 for the purpose of estimating efficacy

Stephen Senn^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › Research › peer-review

4 Citations (Scopus)

Abstract

After a preliminary explanation as to how I came to know Andy Grieve and some remarks about his career and mine and how they have intersected, I consider the design and analysis of trials of vaccines for COVID-19 for the purpose of estimating efficacy. Five large trials, run by the sponsors Pfizer/BioNTech, AstraZeneca/Oxford University, Moderna, Novavax and J&J Janssen are considered briefly. Frequentist approaches to analysis were used for four of the trials but Pfizer/BioNTech nominated a Bayesian approach. The design and analysis of this trial is considered in some detail, in particular as regards the choice of prior distribution. I conclude by drawing some general lessons.

Original language	English
Pages (from-to)	790-807
Number of pages	18
Journal	Pharmaceutical Statistics
Volume	21
Issue number	4
DOIs	https://doi.org/10.1002/pst.2226
Publication status	Published - 1 Jul 2022
Externally published	Yes

Keywords

Bayesian
conditional inference
design of experiments
frequentist
sequential design
vaccine efficacy

Access to Document

10.1002/pst.2226

Cite this

@article{c0241103e41340cfa3a6f42228a1373e,

title = "The design and analysis of vaccine trials for COVID-19 for the purpose of estimating efficacy",

abstract = "After a preliminary explanation as to how I came to know Andy Grieve and some remarks about his career and mine and how they have intersected, I consider the design and analysis of trials of vaccines for COVID-19 for the purpose of estimating efficacy. Five large trials, run by the sponsors Pfizer/BioNTech, AstraZeneca/Oxford University, Moderna, Novavax and J&J Janssen are considered briefly. Frequentist approaches to analysis were used for four of the trials but Pfizer/BioNTech nominated a Bayesian approach. The design and analysis of this trial is considered in some detail, in particular as regards the choice of prior distribution. I conclude by drawing some general lessons.",

keywords = "Bayesian, conditional inference, design of experiments, frequentist, sequential design, vaccine efficacy",

author = "Stephen Senn",

note = "Publisher Copyright: {\textcopyright} 2022 The Author. Pharmaceutical Statistics published by John Wiley & Sons Ltd.",

year = "2022",

month = jul,

day = "1",

doi = "10.1002/pst.2226",

language = "English",

volume = "21",

pages = "790--807",

journal = "Pharmaceutical Statistics",

issn = "1539-1604",

publisher = "John Wiley and Sons Ltd",

number = "4",

}

TY - JOUR

T1 - The design and analysis of vaccine trials for COVID-19 for the purpose of estimating efficacy

AU - Senn, Stephen

PY - 2022/7/1

Y1 - 2022/7/1

N2 - After a preliminary explanation as to how I came to know Andy Grieve and some remarks about his career and mine and how they have intersected, I consider the design and analysis of trials of vaccines for COVID-19 for the purpose of estimating efficacy. Five large trials, run by the sponsors Pfizer/BioNTech, AstraZeneca/Oxford University, Moderna, Novavax and J&J Janssen are considered briefly. Frequentist approaches to analysis were used for four of the trials but Pfizer/BioNTech nominated a Bayesian approach. The design and analysis of this trial is considered in some detail, in particular as regards the choice of prior distribution. I conclude by drawing some general lessons.

AB - After a preliminary explanation as to how I came to know Andy Grieve and some remarks about his career and mine and how they have intersected, I consider the design and analysis of trials of vaccines for COVID-19 for the purpose of estimating efficacy. Five large trials, run by the sponsors Pfizer/BioNTech, AstraZeneca/Oxford University, Moderna, Novavax and J&J Janssen are considered briefly. Frequentist approaches to analysis were used for four of the trials but Pfizer/BioNTech nominated a Bayesian approach. The design and analysis of this trial is considered in some detail, in particular as regards the choice of prior distribution. I conclude by drawing some general lessons.

KW - Bayesian

KW - conditional inference

KW - design of experiments

KW - frequentist

KW - sequential design

KW - vaccine efficacy

UR - http://www.scopus.com/inward/record.url?scp=85133755666&partnerID=8YFLogxK

U2 - 10.1002/pst.2226

DO - 10.1002/pst.2226

M3 - Article

C2 - 35819115

AN - SCOPUS:85133755666

SN - 1539-1604

VL - 21

SP - 790

EP - 807

JO - Pharmaceutical Statistics

JF - Pharmaceutical Statistics

IS - 4

ER -

The design and analysis of vaccine trials for COVID-19 for the purpose of estimating efficacy

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this